Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20200624047908N1
IRCT20200624047908N1
Completed
Phase 3

Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patients: a double-blind randomized clinical trial

Abadan University of Medical Sciences0 sites1,000 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID-19.U07.1COVID-19

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
COVID-19.
Sponsor
Abadan University of Medical Sciences
Enrollment
1000
Status
Completed
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Abadan University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •One of the following signs: Fever \= 37\.8°C at any one time, Dry cough, Severe fatigue, Dyspnea
  • •CT appearance compatible with COVID
  • •O2 Saturation 94% or less

Exclusion Criteria

  • •Renal failure (eGFR \< 30\)
  • •Bradycardia (HR \< 50\)
  • •Taking amiodarone
  • •Previous sofosbuvir use
  • •Pregnancy/lactation
  • •Multi\-organ failure on admission (2 organs or more, excluding lung)
  • •Requiring intubation on admission
  • •Significant arrhythmia in EKG
  • •Allergy to sofosbuvir or daclatasvir
  • •Not consenting to the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1
IRCT20200324046850N2Abadan University of Medical Sciences62
Completed
Phase 3
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCV
IRCT20080901001155N30Rasht University of Medical Sciences16
Recruiting
Phase 2
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infection
DRKS00022203PHARCO CORPORATE90
Completed
Phase 3
Hepatitis C Treatment in a Community-based Setting
IRCT20170213032547N1Kerman University of Medical Sciences110
Completed
Not Applicable
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldHealth Condition 1: B182- Chronic viral hepatitis CHealth Condition 2: D56- Thalassemia
CTRI/2020/06/025910Riten Kumar Samadder70